RhumbLine Advisers’s Alterity Therapeutics ATHE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.27K Hold
2,009
– – ﹤0.01% 3863
2026
Q2
$10.8K Buy
2,009
+39
+2% +$170 ﹤0.01% 3890
2026
Q1
$7.01K Sell
1,970
-157
-7% -$532 ﹤0.01% 3841
2025
Q4
$6.55K Buy
2,127
+1,241
+140% +$4.74K ﹤0.01% 3907
2025
Q3
$3.34K Buy
886
+756
+582% +$3.65K ﹤0.01% 3943
2025
Q2
$533 Hold
130
– – ﹤0.01% 4071
2025
Q1
$450 Buy
+130
New +$498 ﹤0.01% 4061

Other funds holding ATHE

RhumbLine Advisers's ATHE Position: Q3 2026 in Review

RhumbLine Advisers held its Alterity Therapeutics (ATHE) position steady in Q3 2026 at 2,009 shares worth $7.27K. The position accounts for ﹤0.01% of the portfolio, ranked #3863.

RhumbLine Advisers first reported a position in ATHE in Q1 2025 and has held it in 7 quarters since. The position peaked at $10.8K in Q2 2026. 22 funds tracked by Wall St. Rank hold ATHE as of Q3 2026.

  • RhumbLine Advisers held 2,009 shares of Alterity Therapeutics worth $7.27K as of Q3 2026.
  • RhumbLine Advisers left its Alterity Therapeutics share count unchanged in Q3 2026.
  • Alterity Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #3863 holding.
  • RhumbLine Advisers first reported a position in Alterity Therapeutics in Q1 2025 and has held it in 7 quarters since.
  • RhumbLine Advisers's Alterity Therapeutics position peaked at $10.8K in Q2 2026.
  • 22 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.